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Angiotensin-converting enzyme (ACE) inhibitors are widely 
used and effective drugs in the treatment of a broad range 
of cardiovascular and renal disorders. The recent death of a 
patient as a result of angio-oedema related to enalapril use 
prompted us to review all admission records of the intensive 
care units (ICUs) of Victoria, G F Jooste, New Somerset and 
Groote Schuur hospitals.
The index patient was a 54-year-old married man with 2 
children. There was an unconfirmed report of drug allergy 
in his history. He had longstanding hypertension, and had 
received enalapril and atenolol until 2002, when he stopped 
medication of his own accord. In 2004 he visited his general 
practitioner and his blood pressure was found to be elevated 
at 170/100 mmHg. He was commenced on a low-dose thiazide 
diuretic, but after failing to respond he was referred to the local 
clinic in 2005. He was commenced on atenolol and enalapril, 
and at 05h00 the next morning after his first dose of enalapril 
he developed swollen lips and tongue. He was rushed to the 
local emergency unit and was assessed as being in anaphylactic 
shock. He was given intramuscular adrenaline, hydrocortisone 
and promethazine. After 2 hours the patient developed 
stridor and the doctor was unable to intubate him.  He had 2 
cardiopulmonary arrests, and with assistance from a senior 
colleague, an emergency cricothyroidotomy was performed.  
The patient was transferred to Victoria Hospital, and a 
diagnosis of angio-oedema associated with enalapril was made. 
The patient showed signs of severe anoxic brain injury and his 
Glasgow coma scale was 4T. A tracheostomy was performed, 
but there was no neurological recovery and the patient died 2 
weeks later.
After reviewing the records of all admission to the ICUs 
in our academic region we found a further 9 cases of angio-
oedema requiring intubation related to enalapril. Two of these 
patients died of anoxic brain damage, and the remainder 
made uneventful recoveries. A further case of angio-oedema 
requiring intubation was seen by one of the authors (BR) at 
Conradie Hospital. The patient recovered without sequelae. 
One death was reported from the emergency unit of Groote 
Schuur Hospital, viz. a patient who died after failed intubation 
and delayed cricothyroidotomy (Craig Arendse – personal 
communication). All patients were either black or coloured, and 
all patients were receiving enalapril 5 mg or 10 mg twice daily. 
Anecdotally non-life-threatening angio-oedema is frequently 
seen in the hypertension and nephrology clinics at Groote 
Schuur Hospital.
Although angio-oedema is a well-recognised complication of 
ACE inhibitor use, only isolated reports of death have appeared 
in the literature.1,2 However in a study from Columbus, Ohio,3 
7 deaths, all of African Americans, were reported in an autopsy 
series from 1998 to 2000. The OCTAVE study4 was a large pro-
spective study examining the prevalence of angio-oedema re-
lated to the ACE inhibitor enalapril. It involved 12 557 patients, 
including 1 200 blacks, with an overall prevalence rate of 0.68%. 
None of the cases was severe enough to require intubation and 
no deaths were reported. Increased risk for angio-oedema was 
found in blacks (odds ratio (OR) 2.88), in patients with a history 
of drug rash (OR 3.78) or seasonal allergy (OR 1.70), and in 
patients over the age of 65 years (OR 1.65). Most cases occurred 
during the first months of therapy, but it is well recognised that 
angio-oedema can occur more than 10 years after initiation of 
treatment.  
Our reports of death and life-threatening angio-oedema 
out of keeping with trends in other parts of the world are of 
major concern to us. ACE inhibitors are essential and widely 
used drugs for the treatment of hypertension, cardiac disease 
and kidney disease. Several issues need to be addressed. 
The OCTAVE study showed that although not uncommon, 
angio-oedema was seldom severe. This probably does not 
represent the real world situation. In that study, because of 
health professional and patient education and awareness, 
angio-oedema was probably recognised early and therapy 
was terminated immediately. However, in clinical practice 
angio-oedema is frequently missed, misdiagnosed or attributed 
to other causes, and with continuation of treatment attacks 
become worse and even life threatening.5,6 Furthermore, in a 
country where the majority of patients are black the nearly 
3-fold increased prevalence in this population is of significant 
concern. It is also recognised that this complication is related 
to genetic polymorphism (C-2399A variant in XPNPEP2), 
the frequency of which is unknown in the South African 
population.7
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We are also concerned that the angio-oedema we have 
reported is related to enalapril, but this is only anecdotal 
evidence of association. Reports in the literature8 suggest that 
angio-oedema may occur with one ACE inhibitor and not 
another. In our experience angio-oedema was uncommon in 
our clinics when perindopril or ramipril was the ACE inhibitor 
coded for the Western Cape.  A prospective study is needed to 
determine the exact prevalence in South Africa, particularly 
among blacks, but it is important that health professionals 
report severe cases to the Medicines Control Council. 
In the interim there is a need for doctors, nurses and 
pharmacists to inform patients of this complication, and to 
report any suspicious symptoms and signs to their doctor 
immediately. We believe that a ‘black box warning’ should 
appear on all ACE inhibitor medication. ACE inhibitors are 
contraindicated in patients with C1-esterase deficiency and a 
history of angio-oedema. Health professionals should provide 
extra counselling to black patients, elderly persons, and patients 
with a history of drug or seasonal allergy before prescribing 
an ACE inhibitor. It is unfortunate that angio-oedema is not 
listed as a compelling contraindication to ACE inhibitors in the 
latest South African Hypertension Guideline.9 Emergency units 
need to be equipped and have personnel trained to perform 
cricothyroidotomy. Steroids and antihistamines are ineffective 
as the mechanism of the reaction is not allergic but related to 
bradykinin.6 Adrenaline may be helpful but if there is suspicion 
of airway compromise endotracheal intubation should be 
performed immediately and if unsuccessful an emergency 
cricothyroidotomy or tracheostomy should be performed.
Lastly, the Health Department of the Western Cape needs to 
give consideration to coding an alternative ACE inhibitor. 
This report has also been sent to the Medicines Control 
Council of South Africa.
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